Our site uses cookies. Learn more about our use of cookies: cookie policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content Skip to footer
Subscribe Now
News

ALK Reports US FDA Approval of Odactra to Treat Children with House Dust Mite Allergy

Shots:

  • The US FDA has approved Odactra tablet to treat house dust mite (HDM) induced allergic rhinitis, with or without conjunctivitis, in children (5-11yrs.). Regulatory review in Canada is ongoing
  • Approval was based on P-III (MT-12) study assessing Odactra showed significant efficacy & safety in ~1,460 children across North America & EU. Data published in The Lancet Regional Health, Europe
  • Additionally, regulatory review for Itulazax (ALK’s tree tablet) for allergic rhinitis in children is ongoing in EU & Canada; expected to complete in 2025

Ref: Globenewswire | Image: ALK

Related News:- Xcovery Holdings Receives US FDA Approval for Ensacove (Ensartinib) to Treat ALK-Positive Locally Advanced or Metastatic NSCLC

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Tags:
Share Post

You May Also Like

Bayar
March 27, 2025
Bayer Enters Global License Agreement with Suzhou Puhe BioPharma for its PRMT5 Inhibitor
Neurelis
April 17, 2025
Neurelis’ Valtoco Receives the US FDA’s Approval for Acute Treatment of Seizure Clusters
BMS
February 11, 2025
BMS Reports Topline Data from P-II (TRANSCEND FL) trial of Breyanzi for R/R Indolent B-cell non-Hodgkin lymphoma

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]